Top 10 Oncology On the Go Podcast Episodes of 2025: Essential Clinical Insights and Practice-Changing Updates from Experts
Best of Oncology Podcast Series - OncologyEducation | Listen ...
Introduction: The Year Oncology Podcasts Transformed Clinical Practice
Throughout 2025, CancerNetwork's "Oncology On the Go" podcast emerged as a critical resource for oncology professionals seeking up-to-date clinical information, practice-changing data, and psychosocial insights into cancer care. The podcast series featured diverse expert panels including thoracic oncologists, nurse practitioners, clinical pharmacists, gynecologic oncologists, and mental health specialists who synthesized the latest clinical trial data, FDA approvals, and evidence-based treatment strategies into accessible, clinically relevant conversations.
The 2025 podcast year demonstrated a sophisticated evolution in medical education, moving beyond traditional conference presentations to include intimate discussions about the human dimensions of oncology—from managing medication side effects to navigating existential conversations about mortality. This comprehensive analysis reviews the year's 10 most-listened-to episodes, examining the clinical insights, expert perspectives, and actionable guidance that captured audience attention and transformed clinical practice across multiple oncology subspecialties.
#1: Dosing and Adverse Effect Management With Tarlatamab in Small Cell Lung Cancer
Small Cell Lung Cancer: Symptoms & Treatment Options | ACTC
The top podcast episode of 2025 featured Daniel Morgensztern, MD, Professor of Medicine and Clinical Director of Thoracic Oncology at Washington University School of Medicine; Mary Ellen Flanagan, NP, Nurse Practitioner in the Division of Thoracic Oncology at Washington University; and Janelle Mann, PharmD, BCOP, Clinical Oncology Pharmacist at Siteman Cancer Center. This multidisciplinary panel combined physician expertise, nursing perspective, and pharmaceutical knowledge to provide comprehensive guidance on a newly approved therapy.
Clinical Context: The FDA Approval and DeLLphi-301 Trial
The episode centered on tarlatamab-dlle (Imdelltra), a DLL3-targeting bispecific antibody that received FDA accelerated approval in May 2024 for patients with extensive-stage small cell lung cancer (SCLC). Small cell lung cancer represents one of the most aggressive human malignancies, with historically poor prognosis and limited treatment options beyond cytotoxic chemotherapy. For decades, SCLC treatment remained largely unchanged, leaving patients and clinicians with few alternatives to platinum-etoposide regimens that carried substantial toxicity.
Tarlatamab represents a paradigm shift in SCLC management. By targeting Delta-like ligand 3 (DLL3)—a protein expressed on SCLC cells but not on most normal tissues—tarlatamab provides bispecific antibody-mediated tumor destruction with a theoretical mechanism for improved tolerability compared to conventional cytotoxic agents.
Key Clinical Discussion Points
Phase 2 DeLLphi-301 Trial Evidence: The panel reviewed supporting efficacy data from the DeLLphi-301 trial (NCT05060016), which established tarlatamab's activity in chemotherapy-naive and previously treated SCLC patients. This clinical trial demonstrated that bispecific antibody approaches could overcome traditional SCLC chemotherapy refractoriness.
Administration Protocols: Morgensztern detailed tarlatamab administration protocols, emphasizing that this bispecific antibody requires intravenous infusion with specific dosing schedules. Unlike oral medications, the intravenous delivery necessitates patient access to infusion facilities and potential logistics coordination, factors that may impact treatment accessibility in community and rural settings.
Adverse Effect Management Strategies: A critical focus of the episode involved strategies for recognizing and managing tarlatamab-related adverse effects. Mann reviewed pharmacist responsibilities in monitoring for treatment-related toxicities and educating patients about what to expect during therapy. Flanagan contributed nursing perspectives on supportive care measures and patient education approaches that optimize treatment tolerance.
This episode dominated listener engagement because it addressed multiple essential clinical needs simultaneously: it covered a newly approved, practice-changing agent; provided practical administration and monitoring guidance; and offered perspectives from all members of the multidisciplinary cancer care team. For community oncologists practicing without immediate access to specialized SCLC expertise, this episode provided essential guidance for incorporating tarlatamab into clinical practice safely and effectively.
#2: Practice-Changing Lung Cancer Data From ASCO Annual Meeting 2025
Radiation Therapies for Breast Cancer | Jefferson Health
Conference Recap and Expert Discussion
The second most-listened-to episode featured Stephen Liu, MD, Associate Professor of Medicine at Georgetown University and Director of Thoracic Oncology at Georgetown Lombardi Comprehensive Cancer Center, alongside Benjamin Sabari, MD, Assistant Professor at NYU Grossman School of Medicine and Director of High Reliability Organization Initiatives at Perlmutter Cancer Center. This episode provided a live, expert-commentary recap of lung cancer presentations from the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Highlighted Clinical Data: DeLLphi-304 Trial
A central focus involved the phase 3 DeLLphi-304 trial (NCT05740566), which compared tarlatamab directly to chemotherapy as second-line treatment for SCLC. This head-to-head comparison trial provided critical evidence regarding tarlatamab's clinical positioning in the SCLC treatment paradigm. The trial demonstrated superiority of tarlatamab over chemotherapy in extending survival while potentially offering improved quality of life due to reduced toxicity compared to conventional cytotoxic agents.
Beyond tarlatamab, Liu and Sabari highlighted additional practice-changing data from ASCO 2025 affecting non-small cell lung cancer management, including updates on:
Immunotherapy Combinations: Novel combination approaches incorporating checkpoint inhibitors with complementary mechanisms or with targeted agents for specific molecular subsets
Targeted Therapy Advances: Updates on efficacy data for emerging targeted approaches in EGFR, ALK, ROS1, and other actionable mutations
Biomarker-Driven Strategies: Data emphasizing the importance of comprehensive molecular testing in guiding first-line therapy selection
Listeners prioritized this episode because it translated complex conference data into immediately applicable clinical guidance. Rather than overwhelming audiences with full trial results, Liu and Sabari provided curated emphasis on findings most likely to change clinical practice in community and academic settings. The episode effectively bridged the gap between academic conference presentations and community oncology practice.
#3: Oncologists Reflect on COVID-19's Lasting Impact on Cancer Care
Chemotherapy for Metastatic Breast Cancer
The 5-Year Retrospective and Expert Panel
At the 5-year anniversary of the COVID-19 pandemic, this episode convened a diverse expert panel to reflect on how COVID-19 fundamentally altered oncology practice. The panel included:
· Aditya Bardia, MD, MPH, FASCO - Professor, UCLA Division of Hematology/Oncology, Director of Translational Research Integration
· Ritu Salani, MD - Director of Gynecologic Oncology at UCLA
· Scarlett Lin Gomez, PhD, MPH - Professor at UCSF Epidemiology and Biostatistics
· Marwan F. Fakih, MD - Division Chief of GI Medical Oncology at City of Hope
· Elizabeth Zhang-Velten, MD - Radiation Oncologist at Keck Medicine, USC
· Frances Elaine Chow, MD - Neuro-Oncologist at USC Norris Comprehensive Cancer Center
· James B. Yu, MD, MHS, FASTRO - Assistant Professor of Radiation Oncology at Smilow Cancer Hospital
Telemedicine Adoption: The panel discussed how pandemic-forced adoption of telemedicine has permanently transformed cancer care delivery, enabling remote consultations, improved access for rural patients, and novel care models that persist beyond the pandemic emergency.
Treatment Delays and Diagnostic Impact: Oncologists reflected on how pandemic-related healthcare disruptions delayed cancer diagnoses and treatments, with cascading impacts on patient outcomes. The conversation highlighted vulnerability of cancer care systems to healthcare disruptions and the importance of pandemic-resilient care models.
Mental Health and Psychosocial Burden: The panel emphasized how cancer patients simultaneously navigating COVID-19 pandemic stress experienced compounded psychological burden, with ongoing mental health effects persisting even as pandemic restrictions eased.
Health Equity Disruptions: Experts highlighted how pandemic-related healthcare disruptions disproportionately affected marginalized communities, exacerbating existing cancer care disparities.
Resilience and Adaptation: Despite discussing challenges, the panel also emphasized organizational and professional resilience—how the oncology field adapted rapidly to maintain patient care under extraordinary constraints.
Why This Episode Connected Deeply
Unlike clinically focused episodes, this reflection resonated because it validated the complex emotional and professional experiences oncologists endured during the pandemic. By creating space for honest reflection rather than prescriptive guidance, the episode addressed the human dimensions of pandemic practice that formal literature often misses.
#4: Amivantamab Management and Dosing Considerations in EGFR-Mutated NSCLC
T-cell Transfer Therapy - Immunotherapy - NCI
Clinical Context: A Different Lung Cancer Challenge
Following the tarlatamab discussion (episodes #1 and #2), this fourth-ranked episode returned to practical drug management, focusing on amivantamab-vmjw (Rybrevant) for EGFR-mutated non-small cell lung cancer (NSCLC). Where tarlatamab addresses SCLC, amivantamab targets a different patient population: those with activating EGFR mutations representing approximately 40-50% of NSCLC in Asian populations and 10-20% in Western populations.
Expert Panel: Morgensztern, Flanagan, Mann (Returning Contributors)
The same multidisciplinary trio—Morgensztern, Flanagan, and Mann—provided detailed guidance on amivantamab, demonstrating their value as comprehensive expert educators willing to address multiple oncology challenges.
Mechanism of Action: Morgensztern reviewed amivantamab's dual-targeting approach, binding simultaneously to EGFR and MET (hepatocyte growth factor receptor), inducing tumor cell death through multiple pathways. This bispecific antibody mechanism represents an innovation beyond conventional EGFR-targeted approaches like erlotinib or gefitinib.
Key Dosing Strategies: Mann provided detailed information about amivantamab administration via intravenous infusion, including loading phases, maintenance dosing, and schedule modifications based on tolerability and clinical response.
Venous Thromboembolism Risk: A critical safety discussion focused on amivantamab-associated venous thromboembolism (VTE) risk, requiring prophylaxis strategies and patient monitoring. Flanagan discussed nursing interventions and patient education regarding VTE warning signs.
Cutaneous Toxicities: The panel detailed management of amivantamab-associated skin toxicities, ranging from paronychia to acneiform rashes, which while sometimes manageable can substantially impact quality of life if not appropriately managed.
Other Adverse Effects and Mitigation: Beyond VTE and cutaneous toxicities, the panel addressed other treatment-related adverse effects and evidence-based mitigation strategies.
This episode provided essential guidance for oncologists treating EGFR-mutated NSCLC with this emerging bispecific antibody. As amivantamab fills important niches in EGFR+ NSCLC treatment—particularly in patients progressing on earlier-generation EGFR inhibitors—practical management guidance directly impacts patient outcomes.
#5: How to Discuss Death: Exploring Mortality in Cancer Care
CAR T therapies in multiple myeloma: unleashing the future ...
Breaking Clinical Silence on End-of-Life Discussions
Episode #5 shifted focus from pharmaceutical management to profound psychosocial terrain: how oncology professionals address mortality, existential concerns, and end-of-life issues with cancer patients. This episode was created in collaboration with the American Psychosocial Oncology Society, indicating CancerNetwork's recognition that cancer care extends far beyond pharmacology into psychological and spiritual dimensions.
Featured Expert: William S. Breitbart, MD
William S. Breitbart, MD, the Jimmie C. Holland Chair in Psycho-Oncology at Memorial Sloan Kettering Cancer Center, joined host Daniel C. McFarland, DO (Director of the Psycho-Oncology Program at Wilmot Cancer Center) to explore clinical communication approaches around mortality.
Key Themes and Clinical Approaches
Addressing Existential Concerns: Breitbart discussed how cancer patients frequently grapple with existential questions—regarding meaning, legacy, spirituality, and mortality—that extend beyond medical symptom management. Oncology professionals often feel unprepared to address these dimensions.
Fear, Uncertainty, and Depression: The panel explored the constellation of psychological responses to cancer—fear of dying, uncertainty about prognosis, depression regarding altered futures. Rather than treating these as psychiatric complications requiring pharmacotherapy, the discussion emphasized their normative nature in cancer care.
Professional Comfort and Skill Development: McFarland and Breitbart discussed how many oncology professionals feel uncomfortable discussing mortality, leading to avoidance that paradoxically increases patient distress. The episode provided frameworks and specific language oncology professionals can use to open these conversations compassionately.
Spiritual Care Integration: The discussion included how secular oncology services can partner with chaplaincy, social work, and other services to address spiritual and existential concerns comprehensively.
Why This Episode Achieved High Listenership
In an era of increasingly sophisticated cancer pharmacology, this episode reminded oncology professionals that clinical effectiveness requires attending to the whole patient—psychological, spiritual, and existential dimensions alongside physical symptom management. Clinicians hungry for guidance on this frequently-avoided topic embraced this episode enthusiastically.
#6: Cardiovascular Considerations in Breast Cancer Treatment and Survivorship
Chemotherapy for Metastatic Breast Cancer
Emerging Challenge in Oncology: Cardio-Oncology
Episode #6 addressed an increasingly recognized challenge in modern oncology: how cancer therapies—particularly those for breast cancer—can cause cardiovascular complications. As cancer survival rates improve, long-term toxicities including cardiomyopathy, coronary disease, and arrhythmias become clinically significant.
Featured Expert: Joseph S. Wallins, MD, MPH
Joseph S. Wallins, MD, MPH, a cardiology fellow at Weill Cornell Medicine, discussed a manuscript he coauthored published in the June 2025 issue of ONCOLOGY focusing on cardiovascular risk in breast cancer survivors.
Traditional Risk from Anthracyclines and Trastuzumab: The panel reviewed well-established cardiotoxicity from doxorubicin and other anthracycline chemotherapy agents, as well as from HER2-targeted agents like trastuzumab (Herceptin), which can cause cardiomyopathy.
Emerging Risks from Newer Agents: Increasingly, newer breast cancer therapies including CDK4/6 inhibitors, endocrine agents, and immunotherapies carry their own cardiovascular risks requiring monitoring and management.
Preventive Cardiology Approaches: Wallins discussed how cardio-oncology specialists employ preventive strategies—ACE inhibitors, beta blockers, and other cardiac-protective medications—to mitigate therapy-related cardiac dysfunction.
Surveillance Strategies: The panel reviewed optimal cardiac monitoring approaches including echocardiography, biomarkers (troponin, BNP), and functional assessment that enable early detection of cardiac complications.
Breast Cancer Treatment Modification: When cardiotoxicity emerges, clinicians face complex decisions about continuing cancer therapy, switching to alternatives, or modifying doses—requiring nuanced risk-benefit analysis.
As breast cancer therapies have become dramatically more effective, long-term cardiac complications have become a limiting factor in treatment delivery. This episode provided essential guidance for medical and surgical oncologists collaborating with cardiologists to optimize both cancer outcomes and long-term cardiac health.
#7: TILs and Cellular Therapy for Melanoma and Solid Tumors
Adoptive Cell Therapy for Solid Tumors: Current Status in ...
Cellular Therapy: The Next Frontier
Episode #7 explored one of oncology's most exciting frontiers: cellular therapy including tumor-infiltrating lymphocyte (TIL) therapy and CAR-T approaches. This cobranded episode produced in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT) reflected growing clinical interest in adoptive cell therapies as alternatives to traditional chemotherapy and targeted therapy.
Expert Panel: Oncology Pharmacists
The panel consisted of three board-certified oncology pharmacists specializing in cellular therapy:
· Brooke Adams, PharmD, BCOP - Orlando Health Cancer Institute, specializing in stem cell transplantation and cellular therapy
· Natalie Brumwell, PharmD, BCOP - Memorial Sloan Kettering Cancer Center, specializing in cellular therapy
· Bryant A. Clemons, PharmD - University of Kentucky Markey Cancer Center, specializing in hematology and cellular therapy
Featured Therapy: Lifileucel (Amtagvi) for Melanoma
The panel's detailed focus involved lifileucel (Amtagvi), a TIL therapy approved by the FDA for unresectable or metastatic melanoma. This therapy involves extracting tumor-infiltrating lymphocytes from a patient's own melanoma, expanding them ex vivo to billions of cells, and reinfusing them with high-dose interleukin-2 (IL-2).
Mechanism: Lifileucel harnesses the patient's own immune system—cells already present within the tumor microenvironment—amplifying them and redirecting them against cancer cells.
Manufacturing and Logistics: The pharmacists discussed complex manufacturing requirements, including tumor tissue harvesting, cell expansion timelines (taking weeks), and careful patient selection. Unlike small-molecule drugs produced at centralized facilities, cell therapies require coordinated manufacturing and logistics.
Adverse Effect Profile: While lifileucel avoids some conventional chemotherapy toxicities, it carries distinct risks including IL-2-mediated toxidrome (fever, hypotension, respiratory complications, cytokine release syndrome).
Why This Episode Attracted Listeners
Cellular therapies represent transformative approaches for previously refractory malignancies. By providing pharmacist-led education on these complex, novel treatments, the episode democratized access to specialized knowledge among oncology professionals without direct cellular therapy expertise.
#8: Redefining Treatment Paradigms in Low-Grade Serous Ovarian Cancer
Frontiers | Locoregional treatment of de novo stage IV ...
A Rare Tumor Type Gets Its Due
Episode #8 addressed low-grade serous ovarian cancer (LGSC), a relatively rare ovarian cancer subtype representing 5-10% of ovarian cancers but with distinctive clinical behavior requiring specialized management approaches. This partnership with the Foundation for Women's Cancer reflected CancerNetwork's commitment to addressing underrepresented cancer types.
Expert Guest: Kathleen N. Moore, MD, MS
Kathleen N. Moore, MD, MS holds the Virginia Kerley Cade Endowed Chair of Cancer Development at the University of Oklahoma Health Sciences Center and serves as Associate Director of Clinical Research at the Stephenson Cancer Center. Moore represents one of the few gynecologic oncologists with specialized expertise in low-grade serous ovarian cancer.
Distinguishing LGSC from High-Grade Serous Carcinoma: A foundational challenge involves diagnostic accuracy. LGSC exhibits fundamentally different biology, molecular features, and treatment response compared to high-grade serous carcinoma (HGSC), yet both historically received similar treatment approaches. The episode emphasized importance of pathologic confirmation and molecular characterization in treatment planning.
Fertility-Preserving Approaches in Younger Patients: Unlike treatment algorithms for HGSC that prioritize aggressive cytoreduction and platinum-taxane chemotherapy regardless of patient age, LGSC management in young women increasingly emphasizes fertility preservation. Moore discussed surgical approaches and treatment modifications that maintain reproductive capacity in young patients diagnosed with LGSC.
First-Line Standards of Care: The episode reviewed current first-line treatment approaches for LGSC, emphasizing that conventional platinum-based chemotherapy provides modest benefit, leaving room for novel strategies.
Novel Regimens and Letrozole: Moore discussed multiple trials evaluating innovative treatments, particularly those incorporating letrozole (Femara), an aromatase inhibitor. Since LGSC frequently expresses hormone receptors, endocrine approaches offer potential advantages over traditional cytotoxic chemotherapy.
Trial Landscape: The episode reviewed ongoing trials exploring combinations and novel single agents for LGSC treatment, reflecting active research in this previously under-studied malignancy.
For gynecologic oncologists, this episode provided essential guidance on an increasingly recognized distinct tumor type. By elevating LGSC from historical obscurity to center stage, the episode educated clinicians about disease-specific management approaches that optimize outcomes while preserving fertility and quality of life.
#9: Key CAR-T and Transplantation Presentations From 2025 Tandem Meeting
CAR-T cell therapy: current limitations and potential ...
Hematologic Malignancy Focus: CAR-T and Transplantation
Episode #9 shifted focus to hematologic malignancies, featuring a live X Spaces discussion recapping notable abstracts from the 2025 Tandem Meeting—a combined conference of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR).
Rahul Banerjee, MD, FACP - Assistant Professor in the Clinical Research Division at Fred Hutchinson Cancer Center in Seattle
Shernan Holtan, MD - Chief of Blood and Marrow Transplantation and Professor of Medicine at Roswell Park Comprehensive Cancer Center
Tandem Meeting Focus: CAR-T Innovation
The Tandem Meeting represents the primary venue where hematologic malignancy specialists share advances in cellular therapy, particularly CAR-T cell therapies. CAR-T represents perhaps the most clinically mature cellular therapy platform, with multiple FDA-approved products for lymphoid malignancies.
CAR-T Mechanisms: The panel discussed emerging CAR-T designs incorporating novel costimulatory domains, improved tumor-targeting strategies, and approaches to overcome resistance mechanisms that limit earlier-generation CAR-T products.
Disease Applications: Beyond earlier-approved applications in acute lymphoblastic leukemia and certain lymphomas, the panel reviewed emerging data on CAR-T efficacy in additional B-cell and T-cell malignancies.
Manufacturing Innovation: Novel manufacturing approaches enabling shorter production timelines, improved expansion efficiency, and enhanced CAR-T cell quality metrics were discussed.
Transplantation Integration: The panel explored how CAR-T approaches integrate with traditional hematopoietic stem cell transplantation, with some patients receiving CAR-T before or after transplant depending on disease biology and treatment response.
Why Hematology Professionals Valued This Episode
For specialists in hematologic malignancies, this episode provided curated access to the most significant scientific advances presented at a major medical conference. The live format and expert commentary elevated clinical utility beyond what written abstracts could provide.
#10: Men's Sexual Health After Cancer Treatment
Shorter Radiation Course for Some with Early Breast Cancer - NCI
Psychosocial Oncology: Men's Health Issues
The final top-10 episode returned to psychosocial themes, specifically addressing sexual health challenges for men after cancer treatment. This collaboration with the American Psychosocial Oncology Society emphasized that cancer's impact extends far beyond medical parameters into sexual function, identity, and relationship quality.
Daniel C. McFarland, DO - Director of the Psycho-Oncology Program at Wilmot Cancer Center, host of the episode
Christian J. Nelson, PhD - Chief of Psychiatry Service and Attending Psychologist at Memorial Sloan Kettering Cancer Center, codirector of the Psycho-Oncology of Care and Aging Program
Focus Populations: Genitourinary Malignancies
The episode particularly emphasized sexual health challenges in men treated for genitourinary cancers—prostate cancer and testicular cancer—where treatment-related sexual dysfunction directly affects organ systems responsible for sexual function.
Prostate Cancer Treatment Effects: Treatment for prostate cancer—whether via surgery (radical prostatectomy), radiation therapy, or androgen deprivation therapy—frequently causes erectile dysfunction, decreased libido, and ejaculatory dysfunction. The panel discussed prevalence, mechanisms, and management approaches.
Psychological Impact: Beyond physiologic sexual dysfunction, cancer treatment fundamentally alters men's sense of self, masculinity, and sexual identity. Nelson emphasized that psychological impacts often exceed physiologic impairment in determining sexual satisfaction and relationship quality.
Testicular Cancer Considerations: While testicular cancer treatments have become increasingly fertility-preserving, sexual dysfunction and psychological trauma remain significant issues even when physical function is preserved.
Clinician-Initiated Discussions: A central theme involved the critical importance of oncology professionals proactively initiating conversations about sexual health rather than waiting for patients to raise concerns. Many patients experience shame or embarrassment discussing sexual dysfunction with physicians, leading to untreated problems.
Therapeutic Approaches: The panel discussed evidence-based interventions including phosphodiesterase-5 inhibitors (sildenafil, tadalafil), vacuum erection devices, penile injections, and psychological counseling approaches.
Relationship Dimensions: Sexual dysfunction impacts not merely the individual patient but couple relationships. The episode emphasized importance of partner communication and couple-based interventions.
In a field historically uncomfortable discussing male sexuality, this episode provided permission and guidance for oncology professionals to address these critical quality-of-life dimensions. By normalizing these conversations and providing evidence-based management approaches, the episode empowered clinicians to deliver more comprehensive, patient-centered care.
Overarching Themes: What 2025 Podcast Episodes Revealed
Several overarching themes emerge from the year's top 10 episodes:
Multidisciplinary Perspectives: Rather than single-specialty silos, the most impactful episodes featured multidisciplinary panels including physicians, nurses, pharmacists, and mental health specialists, recognizing that comprehensive cancer care requires diverse expertise.
Balance of Clinical Science and Human Dimensions: The year's episodes achieved notable balance between evidence-based clinical guidance and psychosocial, existential dimensions of cancer care—acknowledging that effective oncology requires attending to the whole patient.
Rare Disease Recognition: Multiple episodes focused on relatively uncommon malignancies (SCLC, low-grade serous ovarian cancer) and specialized approaches (cellular therapy), reflecting CancerNetwork's commitment to democratizing specialized knowledge across the oncology community.
Practical Implementation: Episodes transcended abstract knowledge to provide actionable, implementable guidance—specific drug dosing, adverse effect management strategies, and communication frameworks that clinicians could immediately apply in practice.
Conference Data Synthesis: Episodes recapping major medical conferences (ASCO, Tandem) translated complex, voluminous conference data into curated, high-yield clinical insights.
Conclusion: Podcasts as Medical Education Infrastructure
The 2025 "Oncology On the Go" podcast episodes demonstrate that podcast formats have evolved beyond entertainment into essential medical education infrastructure. By combining expert commentary, multidisciplinary perspectives, clinical data synthesis, and psychosocial content, these episodes provided oncology professionals with comprehensive, accessible, timely education that complements but distinctly supplements traditional medical literature and conferences.
For oncology professionals—whether community practitioners with limited access to specialized expertise, academic physicians seeking current evidence syntheses, or psychosocial specialists focused on the human dimensions of cancer care—these top 10 episodes offered invaluable guidance for improving patient outcomes while nurturing the professional and human aspects of oncology practice that sustain careers in this demanding specialty.
Post your opinion
No comments yet.